This application is from an eleven hospital consortium in Southwest Washington and Oregon. Formerly known as the Southwest Washington Community Clinical Oncology Program, now proposing to rename the consortium the Northwest CCOP to reflect a change in geographical representation. This program will continue its efforts to increase the number of patients entered on NCI approved Treatment and Cancer Control Protocols and continue the firm linkages established between the community and three Research Bases (the Southwest Oncology Group, the Fred Hutchinson Cancer Research Center and the Radiation Therapy Oncology Group). In addition, this CCOP will continue to: 1) provide a basis for involving a wider segment of the community in continuing Cancer Control Research and investigate the impacts in the community and, 2) to increase involvement of primary health care providers with CCOP investigations by facilitating wider community participation, and 3) improve care of non-protocol patients. The original program was formed in 1981 with 150 primary care physicians cooperating in the effort. Building on this base in Southwest Washington, and with the addition of Kaiser Permanente of Portland, Oregon, a tight-knit core group of Radiation and Medical Oncologists with interests in Clinical Research and Cancer Control has developed. They have formed a cohesive, controlled, high quality Research Plan enrolling over 270 patients on NCI approved Clinical Treatment Protocols and 457 patients on NCI sponsored Cancer Control programs. This group plans to continue and improve existing research efforts with the intent of entering 202 patients (194.7 credits) on Clinical Trials and 391 patients (246.5 credits) in approved Cancer Control activities. During this funding period, the Principle Investigator has entered over sixty patients on the Thymosin Study at FHRC and NCI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035281-09
Application #
3557713
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1983-09-15
Project End
1995-05-31
Budget Start
1992-06-01
Budget End
1993-05-31
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Multicare Health System
Department
Type
DUNS #
City
Tacoma
State
WA
Country
United States
Zip Code
98405
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 109 publications